Impact Capital Partners’s AbbVie ABBV Stock Holding History

Impact Capital Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$5.96M	Buy	22,796 +73	+0.3%	+$18.7K	1.64%	11
2026 Q2	$5.72M	Buy	22,723 +463	+2%	+$100K	1.56%	13
2026 Q1	$4.84M	Sell	22,260 -4,719	-17%	-$1.05M	1.46%	14
2025 Q4	$6.16M	Buy	26,979 +568	+2%	+$129K	1.83%	8
2025 Q3	$6.12M	Buy	26,411 +1,940	+8%	+$395K	1.84%	9
2025 Q2	$4.54M	Buy	24,471 +334	+1%	+$62.1K	1.49%	11
2025 Q1	$5.06M	Buy	24,137 +2,231	+10%	+$434K	1.83%	7
2024 Q4	$3.89M	Buy	+21,906	New	+$4.03M	1.39%	13

Other funds holding ABBV

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Asset Management One Tokyo, Japan $40B AUM 30.45% 1-Year Est. Return

Cardano Risk Management Rotterdam, Netherlands $18.2B AUM 38.97% 1-Year Est. Return

Sepio Capital Salt Lake City, Utah $2.5B AUM 20.77% 1-Year Est. Return

Hamlin Capital Management New York $4.04B AUM 11.59% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Impact Capital Partners's ABBV Position: Q3 2026 in Review

Impact Capital Partners increased its AbbVie (ABBV) stake by 0.32% in Q3 2026, buying an estimated $18.7K and bringing the position to 22,796 shares worth $5.96M. The position accounts for 1.64% of the portfolio, ranked #11.

Impact Capital Partners first reported a position in ABBV in Q4 2024 and has held it in 8 quarters since. The position peaked at $6.16M in Q4 2025. 1,792 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

Impact Capital Partners held 22,796 shares of AbbVie worth $5.96M as of Q3 2026.
Impact Capital Partners bought 73 AbbVie shares in Q3 2026, an estimated $18.7K.
AbbVie made up 1.64% of Impact Capital Partners's portfolio in Q3 2026, its #11 holding.
Impact Capital Partners first reported a position in AbbVie in Q4 2024 and has held it in 8 quarters since.
Impact Capital Partners's AbbVie position peaked at $6.16M in Q4 2025.
1,792 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Impact Capital Partners's 13F filing for Q3 2026, filed 22 Oct 2026.